SG Americas Securities’s ProShares Ultra CRCL CRCA Stock Holding History

SG Americas Securities’s Portfolio CRCA Stock Details CRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-22,000	Closed	-$908K	–	3735
2026 Q1	$908K	Buy	+22,000	New	+$913K	﹤0.01%	1817

Other funds holding CRCA

Optiver Holding Amsterdam, Netherlands $371B AUM 64.6% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

HCM

Hollencrest Capital Management Newport Beach, California $1.54B AUM 30.1% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Mercer Global Advisors Denver, Colorado $80B AUM 26.12% 1-Year Est. Return

SG Americas Securities's CRCA Position: Q2 2026 in Review

SG Americas Securities sold out of ProShares Ultra CRCL (CRCA) in Q2 2026, closing a stake of 22,000 shares — an estimated $908K sold.

SG Americas Securities first reported a position in CRCA in Q1 2026 and held it in 1 quarter. The position peaked at $908K in Q1 2026. 8 funds tracked by Wall St. Rank hold CRCA as of Q2 2026.

SG Americas Securities reported no remaining ProShares Ultra CRCL position as of Q2 2026 after selling out during the quarter.
SG Americas Securities sold 22,000 ProShares Ultra CRCL shares in Q2 2026, an estimated $908K.
SG Americas Securities first reported a position in ProShares Ultra CRCL in Q1 2026 and held it in 1 quarter.
SG Americas Securities's ProShares Ultra CRCL position peaked at $908K in Q1 2026.
8 funds tracked by Wall St. Rank held ProShares Ultra CRCL as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.